{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:41:56Z","timestamp":1791607316242,"version":"4.3.4"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ctrv.2023.102649","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T04:55:36Z","timestamp":1698728136000},"page":"102649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing"],"prefix":"10.1016","volume":"122","author":[{"given":"Albrecht","family":"Stenzinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7158-2605","authenticated-orcid":false,"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.32074\/1591-951X-252","article-title":"Cholangiocarcinoma","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0015","doi-asserted-by":"crossref","first-page":"100505","DOI":"10.1016\/j.esmoop.2022.100505","article-title":"Role of molecular genetics in the clinical management of cholangiocarcinoma","volume":"7","author":"Normanno","year":"2022","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.ctrv.2023.102649_b0020","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0025","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.ctrv.2023.102649_b0030","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOG.0000000000000611","article-title":"Molecular classification of cholangiocarcinoma","volume":"36","author":"Louis","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0040","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.21037\/jgo-21-776","article-title":"Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma","volume":"12","author":"Zheng","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-pathol-030220-020455","article-title":"Pathogenesis of cholangiocarcinoma","volume":"16","author":"Rodrigues","year":"2021","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0050","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0055","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.31862","article-title":"Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1\/programmed death-ligand 1 blockade responses","volume":"74","author":"Yoon","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hep.32397","article-title":"Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma","volume":"77","author":"Jeon","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0065","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1\u20134 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0070","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","article-title":"Practical considerations in screening for genetic alterations in cholangiocarcinoma","volume":"32","author":"Bekaii-Saab","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0075","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0080","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2023.102649_b0090","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0100","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","article-title":"ESMO Scale for Clinical Actionability of Molecular Targets driving targeted treatment in patients with cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102649_b0105","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78(8)","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.33230","article-title":"Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers","volume":"148","author":"Okamura","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2023.102649_b0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00262-020-02745-y","article-title":"Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0130","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102649_b0135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00428-020-02757-0","article-title":"The leading role of pathology in assessing the somatic molecular alterations of cancer: position paper of the European Society of Pathology","volume":"476","author":"Matias-Guiu","year":"2020","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0145","first-page":"447","article-title":"Next-generation sequencing for the general cancer patient","volume":"17","author":"Avila","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ctrv.2023.102649_b0150","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.csbj.2019.10.004","article-title":"Applications and analysis of targeted genomic sequencing in cancer studies","volume":"17","author":"Bewicke-Copley","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0155","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/17474124.2021.1896967","article-title":"Next generation sequencing for biliary tract cancers","volume":"15","author":"DiPeri","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102649_b0160","doi-asserted-by":"crossref","first-page":"153760","DOI":"10.1016\/j.prp.2022.153760","article-title":"The emerging roles of NGS in clinical oncology and personalized medicine","volume":"230","author":"Hussen","year":"2022","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0165","first-page":"82","article-title":"The importance of molecular testing in the treatment of cholangiocarcinoma","volume":"8","author":"Malka","year":"2020","journal-title":"EMJ Oncol"},{"key":"10.1016\/j.ctrv.2023.102649_b0170","doi-asserted-by":"crossref","DOI":"10.1177\/2374289518766521","article-title":"A next-generation sequencing primer\u2014how does it work and what can it do?","volume":"5","author":"Alekseyev","year":"2018","journal-title":"Acad Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0175","doi-asserted-by":"crossref","first-page":"a034579","DOI":"10.1101\/cshperspect.a034579","article-title":"Whole-genome sequencing in cancer","volume":"9","author":"Zhao","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102649_b0185","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1101\/pdb.top084970","article-title":"RNA sequencing and analysis","volume":"2015","author":"Kukurba","year":"2015","journal-title":"Cold Spring Harb Protoc"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0190","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41597-020-00719-4","article-title":"Paired rRNA-depleted and polyA-selected RNA sequencing data and supporting multi-omics data from human T cells","volume":"7","author":"Chen","year":"2020","journal-title":"Sci Data"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0195","doi-asserted-by":"crossref","first-page":"68","DOI":"10.33590\/emj\/22C9259","article-title":"Demystifying the discussion of sequencing panel size in oncology genetic testing","volume":"7","author":"Dur\u00e3es","year":"2022","journal-title":"Eur Med J"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102649_b0200","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/annonc\/mdx490","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer","volume":"28","author":"Chung","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0205","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102649_b0210","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic profiling of small-bowel adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0215","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1158\/1078-0432.CCR-17-3103","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus","volume":"24","author":"Schrock","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtho.2018.10.008","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer","volume":"14","author":"Schrock","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0225","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jclinpath-2015-203394","article-title":"Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets","volume":"69","author":"Lee","year":"2016","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0230","doi-asserted-by":"crossref","first-page":"100069","DOI":"10.1016\/j.crmeth.2021.100069","article-title":"Probe design for simultaneous, targeted capture of diverse metagenomic targets","volume":"1","author":"Dickson","year":"2021","journal-title":"Cell Rep Methods"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jmoldx.2017.11.010","article-title":"Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management","volume":"20","author":"Hung","year":"2018","journal-title":"J Mol Diagn"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0240","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0245","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.22825","article-title":"Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing","volume":"36","author":"Samorodnitsky","year":"2015","journal-title":"Hum Mutat"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102649_b0250","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0255","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102649_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.620337","article-title":"Allelic dropout is a common phenomenon that reduces the diagnostic yield of PCR-based sequencing of targeted gene panels","volume":"12","author":"Shestak","year":"2021","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102649_b0265","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3390\/diagnostics12071539","article-title":"Target enrichment approaches for next-generation sequencing applications in oncology","volume":"12","author":"Singh","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2023.102649_b0270","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12864-016-3425-4","article-title":"Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller","volume":"18","author":"Xu","year":"2017","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ctrv.2023.102649_b0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12885-015-1015-5","article-title":"Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium","volume":"15","author":"Tops","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102649_b0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12864-017-4428-5","article-title":"Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing","volume":"19","author":"MacConaill","year":"2018","journal-title":"BMC Genomics"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102649_b0285","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.3390\/ijms21186856","article-title":"FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention","volume":"21","author":"De Luca","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2023.102649_b0290","article-title":"Oncogenic gene fusion detection using anchored multiplex polymerase chain reaction followed by next generation sequencing","volume":"149","author":"Seager","year":"2019","journal-title":"J Vis Exp"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0295","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cjp2.308","article-title":"First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma","volume":"9","author":"Neumann","year":"2023","journal-title":"J Pathol Clin Res"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102649_b0300","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/oncolo\/oyac139","article-title":"An expert, multidisciplinary perspective on best practices in biomarker testing in intrahepatic cholangiocarcinoma","volume":"27","author":"Madoff","year":"2022","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0305","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"issue":"29","key":"10.1016\/j.ctrv.2023.102649_b0310","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.2174\/0929867327666200123090153","article-title":"Clinical and translational research challenges in biliary tract cancers","volume":"27","author":"Lamarca","year":"2020","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0315","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/curroncol30010030","article-title":"Pathology of cholangiocarcinomas","volume":"30","author":"Guedj","year":"2022","journal-title":"Curr Oncol"},{"issue":"S1","key":"10.1016\/j.ctrv.2023.102649_b0320","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"issue":"26","key":"10.1016\/j.ctrv.2023.102649_b0325","doi-asserted-by":"crossref","first-page":"42478","DOI":"10.18632\/oncotarget.17199","article-title":"Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center\u2019s experiences","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102649_b0330","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.annonc.2022.07.006","article-title":"Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe","volume":"33","author":"Lamarca","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0335","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/diagnostics12040900","article-title":"Promising genomic testing for biliary tract cancer using endoscopic ultrasound-guided fine-needle aspiration\/biopsy specimens","volume":"12","author":"Kuwatani","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2023.102649_b0340","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0345","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cancers14020392","article-title":"Optimizing the diagnosis and biomarker testing for patients with intrahepatic cholangiocarcinoma: a multidisciplinary approach","volume":"14","author":"Cho","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102649_b0350","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jasc.2020.05.001","article-title":"Small but powerful: the promising role of small specimens for biomarker testing","volume":"9(5)","author":"Gan","year":"2020","journal-title":"J Am Soc Cytopathol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0355","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/13645706.2018.1427597","article-title":"Comparison of biliary brush biopsy and fine needle biopsy in the diagnosis of biliary strictures","volume":"27","author":"Gonzalez-Aguirre","year":"2018","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"02","key":"10.1016\/j.ctrv.2023.102649_b0360","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1055\/s-0043-117949","article-title":"Usefulness of cholangioscopic-guided mapping biopsy using SpyGlass DS for preoperative evaluation of extrahepatic cholangiocarcinoma: a pilot study","volume":"06","author":"Ogawa","year":"2018","journal-title":"Endosc Int Open"},{"key":"10.1016\/j.ctrv.2023.102649_b0365","first-page":"14","article-title":"Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures","author":"Kamp","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102649_b0370","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/cancers13133222","article-title":"Next-generation biomarkers for cholangiocarcinoma","volume":"13","author":"Rodrigues","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0375","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gutjnl-2018-317817","article-title":"Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures","volume":"69","author":"Singhi","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196556","article-title":"Performance of next-generation sequencing on small tumor specimens and\/or low tumor content samples using a commercially available platform","volume":"13","author":"Morris","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0385","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jmoldx.2016.08.002","article-title":"Next-generation sequencing in cancer diagnostics","volume":"18","author":"Corless","year":"2016","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0390","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/modpathol.2013.134","article-title":"The estimation of tumor cell percentage for molecular testing by pathologists is not accurate","volume":"27","author":"Smits","year":"2014","journal-title":"Mod Pathol"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2023.102649_b0395","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cancergen.2015.12.004","article-title":"Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors","volume":"209","author":"Geiersbach","year":"2016","journal-title":"Cancer Genet"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0400","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1369\/0022155420945050","article-title":"Why formalin-fixed, paraffin-embedded biospecimens must be used in genomic medicine: an evidence-based review and conclusion","volume":"68","author":"Mathieson","year":"2020","journal-title":"J Histochem Cytochem"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0405","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/jpm12050750","article-title":"FFPE-based NGS approaches into clinical practice: the limits of glory from a pathologist viewpoint","volume":"12","author":"Cappello","year":"2022","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0410","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1373\/clinchem.2014.223040","article-title":"Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization","volume":"61","author":"Do","year":"2015","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0415","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/bio.2018.0046","article-title":"National Cancer Institute biospecimen evidence-based practices: harmonizing procedures for nucleic acid extraction from formalin-fixed, paraffin-embedded tissue","volume":"16","author":"Greytak","year":"2018","journal-title":"Biopreserv Biobank"},{"key":"10.1016\/j.ctrv.2023.102649_b0420","unstructured":"International Organization for Standardization (ISO\u00ae). ISO 20166-3:2018: Molecular in vitro diagnostic examinations \u2014 specifications for pre-examination processes for formalin-fixed and paraffin-embedded (FFPE) tissue \u2014 part 3: isolated DNA. Accessed April 12, 2023. https:\/\/www.iso.org\/standard\/69803.html."},{"issue":"7","key":"10.1016\/j.ctrv.2023.102649_b0425","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0000000000000196","article-title":"Sample features associated with success rates in population-based EGFR mutation testing","volume":"9","author":"Shiau","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102649_b0430","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102649_b0435","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102649_b0440","doi-asserted-by":"crossref","first-page":"100226","DOI":"10.1016\/j.jhepr.2021.100226","article-title":"Cell of origin in biliary tract cancers and clinical implications","volume":"3","author":"Moeini","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2023.102649_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0450","first-page":"890","article-title":"Liquid biopsy, ctDNA diagnosis through NGS","volume":"11","author":"Lin","year":"2021","journal-title":"Life (Basel)"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102649_b0455","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3390\/cancers13184581","article-title":"Liquid biopsy from bile-circulating tumor DNA in patients with biliary tract cancer","volume":"13","author":"Han","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/cancers13010039","article-title":"Bile-based cell-free DNA analysis is a reliable diagnostic tool in pancreatobiliary cancer","volume":"13","author":"Driescher","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0465","doi-asserted-by":"crossref","first-page":"100275","DOI":"10.1016\/j.esmoop.2021.100275","article-title":"Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer","volume":"6","author":"Gou","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0470","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0475","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4251\/wjgo.v13.i9.1073","article-title":"Potential utility of liquid biopsies in the management of patients with biliary tract cancers: a review","volume":"13","author":"Shotton","year":"2021","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0480","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0485","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"issue":"466","key":"10.1016\/j.ctrv.2023.102649_b0490","doi-asserted-by":"crossref","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0495","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1097\/HS9.0000000000000727","article-title":"Controversies in the interpretation of liquid biopsy data in lymphoma","volume":"6","author":"Pirosa","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.ctrv.2023.102649_b0500","article-title":"The potential use of dynamics changes of ctDNA and cfDNA in the perioperative period to predict the recurrence risk in early NSCLC","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102649_b0505","doi-asserted-by":"crossref","first-page":"e2200261","DOI":"10.1200\/PO.22.00261","article-title":"Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples","volume":"6","author":"Husain","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0510","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21037\/tlcr.2020.01.01","article-title":"Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications","volume":"9","author":"Pasquale","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"41","key":"10.1016\/j.ctrv.2023.102649_b0515","doi-asserted-by":"crossref","first-page":"66595","DOI":"10.18632\/oncotarget.10704","article-title":"Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma","volume":"7","author":"Rachiglio","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0520","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102649_b0525","doi-asserted-by":"crossref","first-page":"362","DOI":"10.37349\/etat.2022.00087","article-title":"Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives","volume":"3","author":"Arrichiello","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.ctrv.2023.102649_b0530","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12864-022-08837-6","article-title":"Results and lessons from dual extraction of DNA and RNA from formalin-fixed paraffin-embedded breast tumor tissues for a large cancer epidemiologic study","volume":"23","author":"Ondracek","year":"2022","journal-title":"BMC Genomics"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0535","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00432-021-03774-5","article-title":"Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience","volume":"148","author":"Welland","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102649_b0540","unstructured":"Foundation Medicine. FoundationOne CDx technical specifications. Accessed May, 2023. https:\/\/info.foundationmedicine.com\/hubfs\/FMI%20Labels\/FoundationOne_Liquid_CDx_Label_Technical_Info.pdf."},{"key":"10.1016\/j.ctrv.2023.102649_b0545","unstructured":"U.S. Food and Drug Administration. Premarket Approval (PMA). FoundationOne CDx (F1CDx). Accessed September 7, 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P170019S013."},{"key":"10.1016\/j.ctrv.2023.102649_b0550","unstructured":"Thermo Fisher Scientific. Oncomine Dx Target Test\u2014Europe. Accessed September 7, 2022. https:\/\/www.thermofisher.com\/uk\/en\/home\/clinical\/diagnostic-testing\/condition-disease-diagnostics\/oncology-diagnostics\/oncomine-dx-target-test\/oncomine-dx-target-test-us-only.html."},{"key":"10.1016\/j.ctrv.2023.102649_b0555","unstructured":"U.S. Food and Drug Administration. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. Accessed May 31, 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma."},{"key":"10.1016\/j.ctrv.2023.102649_b0560","doi-asserted-by":"crossref","unstructured":"Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, et al. Structure and content of the EU-IVDR : current status and implications for pathology. Pathologie (Heidelb). 2023:1\u201313. doi:10.1007\/s00292-022-01176-z.","DOI":"10.1007\/s00292-022-01176-z"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0565","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/jpm12010072","article-title":"Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe","volume":"12","author":"Horgan","year":"2022","journal-title":"J Pers Med"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102649_b0570","doi-asserted-by":"crossref","first-page":"958","DOI":"10.5858\/arpa.2015-0507-RA","article-title":"Next-generation sequencing informatics: challenges and strategies for implementation in a clinical environment","volume":"140","author":"Roy","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102649_b0575","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00428-016-2025-7","article-title":"Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL","volume":"470","author":"Deans","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2023.102649_b0580","article-title":"Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics","volume":"9:851","author":"Petrackova","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102649_b0585","unstructured":"Vasinek M. OLGEN coverage limit. Accessed January 16, 2023. https:\/\/github.com\/mvasinek\/olgen-coverage-limit."},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0590","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0595","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.ctrv.2023.102649_b0600","unstructured":"ClinGen - Clinical Genome Resource. The ClinGen Evidence Repository. Accessed July 17, 2023. https:\/\/erepo.clinicalgenome.org\/evrepo\/."},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0605","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41588-020-0603-8","article-title":"A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer","volume":"52","author":"Wagner","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2023.102649_b0610","unstructured":"National Institutes of Health - National Cancer Institute. GDC Data Portal. Accessed August 3, 2023. https:\/\/portal.gdc.cancer.gov\/repository."},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0615","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/CCI.19.00169","article-title":"Collaborative, multidisciplinary evaluation of cancer variants through virtual molecular tumor boards informs local clinical practices","author":"Rao","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.ctrv.2023.102649_b0620","article-title":"Molecular tumor board-assisted care in an advanced cancer population: results of a phase II clinical trial","volume":"6","author":"Miller","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0625","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41416-022-02120-x","article-title":"Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a comprehensive cancer centre","volume":"128","author":"Scheiter","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102649_b0630","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2023.01.019","article-title":"Molecular tumour board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience","volume":"183","author":"Repetto","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102649_b0635","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102649_b0640","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/diagnostics10080521","article-title":"Next generation sequencing for gene fusion analysis in lung cancer: a literature review","volume":"10","author":"Bruno","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102649_b0645","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tranon.2019.02.012","article-title":"An integrated next-generation sequencing system for analyzing DNA mutations, gene fusions, and RNA expression in lung cancer","volume":"12","author":"Haynes","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ctrv.2023.102649_b0650","unstructured":"Archer DX. FusionPlex\u00ae Solid Tumor. Accessed December 28, 2020. https:\/\/archerdx.com\/research-products\/solid-tumor-research\/fusionplex-solid-tumor\/."},{"key":"10.1016\/j.ctrv.2023.102649_b0655","unstructured":"QIAGEN\u00ae. QIAseq targeted DNA panels. Accessed August 31, 2023. https:\/\/www.qiagen.com\/us\/products\/discovery-and-translational-research\/next-generation-sequencing\/dna-sequencing\/somatic-panels\/qiaseq-targeted-dna-panels?catno=333515."},{"key":"10.1016\/j.ctrv.2023.102649_b0660","unstructured":"Foundation Medicine. FoundationOne\u00aeCDx. Accessed December 28, 2020. https:\/\/www.foundationmedicine.com\/genomic-testing\/foundation-one-cdx."},{"key":"10.1016\/j.ctrv.2023.102649_b0665","unstructured":"Kew. CANCERPLEX. Accessed September 7, 2023. https:\/\/kewinc.com\/cancerplex-overview\/."},{"issue":"4","key":"10.1016\/j.ctrv.2023.102649_b0670","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/pme-2017-0011","article-title":"Clinical application of a cancer genomic profiling assay to guide precision medicine decisions","volume":"14","author":"Eifert","year":"2017","journal-title":"Per Med"},{"key":"10.1016\/j.ctrv.2023.102649_b0675","unstructured":"Memorial Sloan Kettering Cancer Center. MSK-IMPACT: a targeted test for mutations in both rare and common cancers. Accessed October 10, 2020. https:\/\/www.mskcc.org\/msk-impact#."},{"key":"10.1016\/j.ctrv.2023.102649_b0680","unstructured":"PathGroup. SmartGenomics. Accessed May 31, 2023. http:\/\/www.pathgroup.com\/oncology\/smartgenomics\/."},{"key":"10.1016\/j.ctrv.2023.102649_b0685","unstructured":"PathGroup. Test update-SmartGenomicsTM Complete & New Smart GenomicsTM Cancer Specific Profiles. Accessed May 31, 2023. http:\/\/www.pathgroup.com\/test-update-smartgenomics-complete-new-smartgenomics-cancer-specific-profiles\/."},{"key":"10.1016\/j.ctrv.2023.102649_b0690","unstructured":"NeoGenomics. NeoTYPE\u00ae discovery profile for solid tumors. Accessed December 28, 2020. https:\/\/neogenomics.com\/test-menu\/neotype-discovery-profile-solid-tumors."},{"key":"10.1016\/j.ctrv.2023.102649_b0695","unstructured":"OmniSeq Corporation. OmniSeq Comprehensive. Accessed March 10, 2021. https:\/\/oncology.labcorp.com\/tests\/831177\/omniseq-insight-solid-tumor-ngs-panel-dna-and-rna."},{"key":"10.1016\/j.ctrv.2023.102649_b0700","unstructured":"Tempus. Genomic profiling. Accessed December 28, 2020. https:\/\/www.tempus.com\/genomic-profiling\/."},{"key":"10.1016\/j.ctrv.2023.102649_b0705","unstructured":"ThermoFisher Scientific. Oncology diagnostics. Accessed December 28, 2020. https:\/\/www.thermofisher.com\/us\/en\/home\/clinical\/diagnostic-testing\/condition-disease-diagnostics\/oncology-diagnostics.html."},{"key":"10.1016\/j.ctrv.2023.102649_b0710","unstructured":"ThermoFisher Scientific. Oncomine Comprehensive Assay Plus. Accessed December 28, 2020. https:\/\/www.thermofisher.com\/us\/en\/home\/clinical\/preclinical-companion-diagnostic-development\/oncomine-oncology\/oncomine-cancer-research-panel-workflow\/oncomine-comprehensive-assay-plus.html."},{"key":"10.1016\/j.ctrv.2023.102649_b0715","unstructured":"Thermo Fisher Scientific. Oncomine\u2122 Precision Assay GX. Accessed September 7, 2023. https:\/\/www.thermofisher.com\/order\/catalog\/product\/A46291?SID=srch-hj-A46291."},{"key":"10.1016\/j.ctrv.2023.102649_b0720","unstructured":"ThermoFisher Scientific. Clinical Test Report : Oncomine\u2122 Dx Target Test US v10.0. Accessed September 7, 2023. https:\/\/assets.thermofisher.com\/TFS-Assets\/LSG\/brochures\/oncomine-dx-target-test-sample-report.pdf."},{"key":"10.1016\/j.ctrv.2023.102649_b0725","unstructured":"SOPHiA Genetics. SOPHiA Solid Tumor Solutions. Accessed January 25, 2023. https:\/\/www.sophiagenetics.com\/clinical\/oncology\/solid-tumors\/sophia-solid-tumor-solutions\/."},{"key":"10.1016\/j.ctrv.2023.102649_b0730","unstructured":"Foundation Medicine. FoundationOne\u00aeLiquid CDx. Accessed December 28, 2020. https:\/\/www.foundationmedicine.com\/test\/foundationone-liquid-cdx."},{"key":"10.1016\/j.ctrv.2023.102649_b0735","unstructured":"Memorial Sloan Kettering Cancer Center. MSK-ACCESS\u00ae. Accessed March 22, 2022. https:\/\/www.mskcc.org\/departments\/division-solid-tumor-oncology\/early-drug-development-service-phase-clinical-trials\/precision-medicine-approach\/msk-access."},{"key":"10.1016\/j.ctrv.2023.102649_b0740","unstructured":"Integrated DNA Technologies. LiquidPlex RUO panel for Illumina\u00ae. Accessed March 22, 2023."},{"key":"10.1016\/j.ctrv.2023.102649_b0745","unstructured":"Guardant Health. Guardant360\u00ae CDx. Accessed December 28, 2020. https:\/\/guardant360cdx.com\/guardant360-cdx\/."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:30:49Z","timestamp":1759656649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223001421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":149,"alternative-id":["S0305737223001421"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102649","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102649"}}